In a major regulatory update, the U.S. Food and Drug Administration (FDA) has announced the discontinuation of the Risk Evaluation and Mitigation Strategy (REMS) program…
In a significant development for the treatment of schizophrenia, the FDA has recently approved Cobenfy, a novel medication that targets schizophrenia through non-dopaminergic pathways. This…
In a significant stride forward in mental health treatment, the Food and Drug Administration (FDA) has recently approved Iloperidone for the management of bipolar disorder.…
On Sep 28, 2023: Fabre-Kramer Pharmaceuticals Announcesd the FDA Approval of EXXUA™, the Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder…
On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of…
Viloxazine ER (Qelbree) was initially approved for pediatric ADHD and now had received FDA approval for the management of ADHD in adult patients. We have…
Today FDA has approved the first sublingual medication, IGALMI (Dexmedetomidine) for the management of acute agitation in indications discussed below. We have summarized this medication…
On Jan 10, 2022, FDA has approved this new medication for treatment of adults with insomnia: Quviviq (daridorexant). This FDA approval is based on the…
Sep 01, 2021. Today FDA approved the first and only 6 monthly long-acting injectable for schizophrenia treatment: Invega Hafyera. We have summarized Invega Hafyera clinical…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
